Imaging in Drug Discovery and Early Clinical Trials

In this monograph the contribution of imaging modalities to the various stages of drug discovery and development, from early target validation to their use in clinical development programs, is described. Chapters are devoted to the description of the drug discovery process as such, to the various imaging modalities being used both preclinically and clinically, to applications of imaging during the optimization of a lead compound (addressing issues such as bioavailability and efficacy) and during the drug safety evaluation. A chapter describes imaging biomarkers, their development, advantages and the potential pitfalls associated with their use. In the translation of imaging tools from animals to man regulatory issues have to be addressed, which are dealt with in a separate section.

The monograph provides a comprehensive overview on the role of imaging in drug discovery today and discusses major developments and trends both with regard to technologies and applications.

• Drug Discovery
• Imaging
• Trend
• fluorescence
• lead
• optimization

• Novartis International AG, Basel, Switzerland

  Paul L. Herrling

• Novartis Institute for Tropical Diseases, Singapore, Singapore

  Alex Matter

• Institute for Biomedical Engineering, University of Zürich/ETH Zürich, Zürich, Switzerland

  Markus Rudin

Policies and ethics